Arteris Inc

Arteris insider sales surge: CEO and Bayview Legacy off‑load $2.7M of shares amid bullish momentum, hinting at portfolio rebalancing and potential price impact.

Arteris insider trading shows modest shifts: Claudia Munce’s recent buy signals confidence amid tax‑related sales, boosting investors’ view of the company’s growth potential.

Arteris CEO’s 10(b)(5)(1) sales show disciplined liquidity, not panic – still strong growth, 52‑week highs, and a diversified semiconductor pipeline.

Arteris insider selling: Bayview Legacy’s recent March sales reveal CEO K. Charles Janac’s liquidity strategy amid weak earnings, prompting investors to monitor future trades for market shifts.

Arteris insider selling continues: Bayview Legacy’s 10‑b‑5‑1 trades shed 1.3 M shares, raising questions on future upside and valuation.

Arteris COO Moll Laurent R’s 37,553 RSU “buy” shows a shift toward long‑term equity, signaling confidence amid volatile semiconductor markets and a potential bullish cue for investors.

Bayview Legacy’s 47k‑share sale of Arteris Inc. shows a cautious, planned divestiture amid a recent rally, offering investors insight into insider timing and potential short‑term value harvesting.

Arteris CEO’s planned insider sales reveal a steady, liquidity‑focused exit strategy that may temper investor sentiment while offering clearer ownership insight.

Alpern Paul L’s disciplined 10b‑5‑1 buy at Arteris signals insider confidence amid volatility, hinting at long‑term upside for the IP‑heavy semiconductor firm.

Arteris insider sale: 2,116 shares sold at $17.79 under a 10(b)(5)(1) plan, indicating confidence while keeping liquidity – what this means for investors.